CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The CARE consortium is focused on rapidly developing therapeutics for COVID-19 through drug repositioning and new drug discovery. It aims to identify effective small molecules and antibodies to combat SARS-CoV-2 and related coronaviruses, advancing promising candidates into clinical trials.
The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in this century.
According to the World Health Organisation Situation Report of March 28th 2020, 571,659 patients were diagnosed with Coronavirus Disease 2019 (COVID-19) and 26,493 deaths were reported globally.
The wide spectrum of clinical symptoms, disease severity in high risk individuals, transmission efficiency and high mortality, raises an immediate need fo…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Bordeaux
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Creteil
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Belgium, Beerse
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Switzerland, Glattpark
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
